BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17196514)

  • 41. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
    Farhat MH; El-Saghir NS; Shamseddine AI
    Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
    Mizuno Y; Chin K; Ando N; Oike E
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1293-6. PubMed ID: 16969027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
    Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
    [No Abstract]   [Full Text] [Related]  

  • 45. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.
    Christodoulou C; Klouvas G; Pateli A; Mellou S; Sgouros J; Skarlos DV
    Anticancer Res; 2003; 23(1B):737-44. PubMed ID: 12680177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel plus bevacizumab for metastatic breast cancer.
    Haines IE; Miklos GL
    N Engl J Med; 2008 Apr; 358(15):1637; author reply 1637-8. PubMed ID: 18403775
    [No Abstract]   [Full Text] [Related]  

  • 47. [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
    Suzuki M; Kimijima I; Ishii M
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1519-23. PubMed ID: 19755824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
    Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
    J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge.
    Azim HA; Azim H; Peccatori FA
    Expert Rev Clin Immunol; 2010 Nov; 6(6):821-6. PubMed ID: 20979546
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
    Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
    J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
    Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
    Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
    Wang LP; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
    [No Abstract]   [Full Text] [Related]  

  • 53. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
    Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab.
    Lazzati V; Zygoń J; Lohsiriwat V; Veronesi P; Petit JY
    Aesthetic Plast Surg; 2010 Dec; 34(6):796-7. PubMed ID: 20567970
    [No Abstract]   [Full Text] [Related]  

  • 57. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
    Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature.
    Gadducci A; Cosio S; Fanucchi A; Nardini V; Roncella M; Conte PF; Genazzani AR
    Anticancer Res; 2003; 23(6D):5225-9. PubMed ID: 14981994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
    Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of pregnancy on the pharmacokinetics of paclitaxel: a case report.
    Lycette JL; Dul CL; Munar M; Belle D; Chui SY; Koop DR; Nichols CR
    Clin Breast Cancer; 2006 Oct; 7(4):342-4. PubMed ID: 17092404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.